Form 4: Bicara Therapeutics COO Boosts Stake with Option Exercise

Bicara Therapeutics President and COO Ryan Cohlhepp exercised stock options to acquire 25,000 shares, increasing his direct ownership.

Summary

• Ryan Cohlhepp, President and COO of Bicara Therapeutics Inc. (BCAX), exercised an Incentive Stock Option (ISO) to acquire 25,000 shares of common stock.
• The transaction occurred on December 26, 2025, at an exercise price of $4.4369 per share.
• Following this transaction, Cohlhepp directly beneficially owns 214,141 shares of common stock.
• The exercised options were part of a grant where shares vest in sixteen equal quarterly installments following October 4, 2022.
• After the exercise, Cohlhepp retains 39,909 derivative securities (stock options) with an expiration date of October 4, 2032.
• The transaction was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-scheduled purchase.

Sentiment

Score: 8

Explanation: The exercise of stock options and subsequent holding of shares by a key executive is a strong positive signal, indicating confidence in the company's future value.

Positives

• The exercise and hold of stock options by a key executive like the President and COO signals strong confidence in the company's future prospects.
• Increased insider ownership aligns management's interests more closely with those of shareholders.

Future Outlook

The exercise and retention of shares by a high-ranking executive suggests a positive long-term outlook for Bicara Therapeutics, indicating management's belief in the company's future growth and value appreciation.

Management Comments

• The action of exercising and holding shares reflects management's confidence in the company's strategic direction and future performance.

Industry Context

Insider transactions, particularly exercises and holds by senior executives in the biotechnology sector, are often viewed by investors as a positive indicator of future company performance, especially given the inherent risks and long development cycles in the industry. It suggests that the executive believes the company's pipeline or strategic initiatives will yield significant returns.

Stakeholder Impact

• Shareholders: Increased insider ownership can be perceived as a positive signal, potentially boosting investor confidence.
• Employees: Demonstrates leadership's commitment to the company's long-term success.

Next Steps

• Continued vesting of remaining stock options in sixteen equal quarterly installments following October 4, 2022, subject to continued service.

Key Dates

Recommendation

The exercise of stock options and retention of shares by a high-level executive like the President and COO indicates strong insider confidence in Bicara Therapeutics' future. This action aligns management's interests with shareholders and suggests a belief in long-term value creation, making it a positive signal for existing investors to hold their positions.

Keywords

Bicara Therapeutics, BCAX, Ryan Cohlhepp, Insider Transaction, Form 4, Stock Option Exercise, Biotechnology, Executive Ownership, Rule 10b5-1